Partial
Needs Improvement
Patient Risk:
Moderate
Summary
Partially aligned: the claim about avoiding TYGACIL in patients with known tetracycline-class hypersensitivity is supported by the provided label text. Many other claims about specific allergic reaction manifestations, timing, management, and excipients are not supported or not present in the supplied prescribing information excerpts.
Category Scores
Accurate Statements
Avoid TYGACIL (tigecycline) in patients with known hypersensitivity to tetracycline-class antibacterial drugs.
Section 5.3 Anaphylactic Reactions: “TYGACIL is structurally similar to tetracycline-class antibacterial drugs and should be avoided in patients with known hypersensitivity to tetracycline-class antibacterial drugs.”
Unsupported Statements
Tigecycline carries a documented risk of hypersensitivity reactions.
The provided excerpts specifically discuss anaphylactic reactions, but hypersensitivity reactions broadly (as a documented category) are not explicitly stated in the supplied text.
Tigecycline hypersensitivity reactions can include rash, itching, hives, facial swelling, wheezing, difficulty breathing.
No such specific hypersensitivity/anaphylaxis manifestations are included in the supplied label excerpts.
Severe anaphylaxis in rare cases.
No “rare cases” frequency statement is present in the supplied excerpts.
Tigecycline prescribing information lists allergic reactions among its adverse effects.
The provided excerpts do not list “allergic reactions” as adverse effects.
Tigecycline itself is the primary allergen.
Not stated in the supplied label excerpts.
Some tigecycline formulations contain inactive ingredients such as lactose or other excipients that can provoke reactions in sensitive individuals.
No excipient- or lactose-specific information is present in the supplied label excerpts.
Symptoms of allergic reactions usually develop within minutes to hours of infusion.
No timing window for allergic reaction symptom onset is present in the supplied excerpts.
Severe allergic reactions to tigecycline can progress to anaphylactic shock.
The supplied text states anaphylactic reactions may be life-threatening, but does not describe progression to “anaphylactic shock.”
Anaphylactic shock from tigecycline requires immediate epinephrine.
No treatment recommendation for anaphylaxis (e.g., epinephrine) is included in the supplied excerpts.
Allergic reaction symptoms … may include … (listed symptoms).
Specific symptom lists (beyond “anaphylactic reactions”) are not present in the supplied excerpts.
Allergic reactions … can be managed with supportive care, antihistamines, corticosteroids, or epinephrine depending on severity.
No management regimen is provided in the supplied excerpts.
An allergic reaction to tigecycline should be documented to guide future antibiotic choices.
Not stated in the supplied excerpts.
Severe hypersensitivity reactions … are uncommon but have been reported in post-marketing surveillance.
No post-marketing frequency statement is present in the supplied excerpts.
Mild skin reactions occur more frequently with tigecycline.
Not stated in the supplied excerpts.
Mild skin reactions … managed by slowing the infusion rate or switching therapy.
No such management guidance for mild skin reactions is present in the supplied excerpts.
Contradictions
Important Omissions
For the claim that mentions hypersensitivity/anaphylaxis, the supplied excerpts only explicitly support avoidance in tetracycline-class hypersensitivity and that anaphylactic reactions may be life-threatening; details about rash/itching/hives/facial swelling/wheezing/difficulty breathing, timing, and treatment are absent.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported specifics about symptoms, timing, and management could mislead users if treated as label-accurate. The one supported avoidance statement aligns with the provided label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Improvement
Primary Issue
Many hypersensitivity/anaphylaxis details are not supported by the provided prescribing information excerpts.
Suggested Improvement
Restrict statements to what is present in the supplied label text (e.g., avoidance in patients with known tetracycline-class hypersensitivity; anaphylactic reactions may be life-threatening) and avoid adding symptom lists, onset timing, management steps, excipient claims, or frequency/post-marketing assertions unless supported by the full label.